PROCEPT BioRobotics (NASDAQ:PRCT) and Rockwell Medical (NASDAQ:RMTI) Head-To-Head Review

Rockwell Medical (NASDAQ:RMTI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership

23.3% of Rockwell Medical shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 4.6% of Rockwell Medical shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Rockwell Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.33%	-14.03%	-8.90%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Earnings & Valuation

This table compares Rockwell Medical and PROCEPT BioRobotics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.39 million	0.41	-$5.31 million	($1.34)	-5.28
PROCEPT BioRobotics	$337.34 million	3.10	-$95.57 million	($1.94)	-9.42

Rockwell Medical has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rockwell Medical has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Rockwell Medical and PROCEPT BioRobotics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	2	0	1	0	1.67
PROCEPT BioRobotics	2	9	2	3	2.38

Rockwell Medical currently has a consensus price target of $20.00, suggesting a potential upside of 182.49%. PROCEPT BioRobotics has a consensus price target of $25.50, suggesting a potential upside of 39.57%. Given Rockwell Medical’s higher possible upside, analysts plainly believe Rockwell Medical is more favorable than PROCEPT BioRobotics.

Summary

Rockwell Medical beats PROCEPT BioRobotics on 9 of the 15 factors compared between the two stocks.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.